Atripla (Bristol Myers Squibb & Gilead Sciences, LLC)
Welcome to the PulseAid listing for the Atripla drug offered from Bristol Myers Squibb & Gilead Sciences, LLC. This Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Bristol Myers Squibb & Gilead Sciences, LLC |
| NON-PROPRIETARY NAME: | efavirenz, emtricitabine, and tenofovir disoproxil fumarate |
| SUBSTANCE NAME: | EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Cytochrome P450 3A Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],Cytochrome P450 2C9 Inhibitors [MoA],Cytochrome P450 2C19 Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2006-07-20 |
| END MARKETING DATE: | 0000-00-00 |
Atripla HUMAN PRESCRIPTION DRUG Details:
| Item Description | Atripla from Bristol Myers Squibb & Gilead Sciences, LLC |
| LABELER NAME: | Bristol Myers Squibb & Gilead Sciences, LLC |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 600; 200; 300(mg/1; mg/1; mg/1) |
| START MARKETING DATE: | 2006-07-20 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 15584-0101_c4b406d5-68fe-4c31-a0cb-d4408be493cf |
| PRODUCT NDC: | 15584-0101 |
| APPLICATION NUMBER: | NDA021937 |
Other EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Pharmaceutical Manufacturers / Labelers:
